OncoMatch/Clinical Trials/NCT07145047
Clinical Study of Oncolytic Virus in Glioblastoma
Is NCT07145047 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies oncolytic virus for glioblastoma (gbm).
Treatment: oncolytic virus — This clinical trial aims to evaluate whether an oncolytic viral agent can treat recurrent glioblastoma. It will also assess the safety and tolerability of the oncolytic viral agent. The primary question it seeks to answer is: What medical problems do participants experience when injected with the oncolytic viral agent? Researchers will administer the oncolytic viral agent via intratumoral injection to determine its efficacy in treating recurrent glioblastoma. Participant Procedures: Receive the initial injection, followed by additional injections every 2-4 weeks for a total of 6 injections. Undergo physical examinations and tests every 2 to 4 weeks. Record their symptoms, hematological test results, and imaging findings.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiotherapy
Time from the last radiotherapy/surgery is more than 28 days
Must have received: surgery
Time from the last radiotherapy/surgery is more than 28 days
Must have received: antitumor therapy (vincristine, nitrosoureas, bevacizumab, temozolomide)
Most recent antitumor therapy must have been completed within the specified time prior to treatment: vincristine 2 weeks, nitrosoureas 4 weeks, bevacizumab 4 weeks, temozolomide 6 weeks
Cannot have received: gene transfer therapy
Patients who have received gene transfer therapy
Cannot have received: oncolytic virus
treated with any type of oncolytic virus
Lab requirements
Blood counts
Hematological indicators are normal
Kidney function
kidney function are normal
Liver function
liver function are normal
Hematological indicators, kidney and liver function are normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify